I'll take a crack at it. I don't have a definitive answer for you.
Certainly I would say that on the international scene that's challenging, especially where it's a commercial “survival of the fittest” approach. But I think where there has been some success—and coming back to some extent to your red tape issue—is in some of the collaborative efforts within Canada around, for instance, how clinical trials are done. It can be difficult for industry to conduct a clinical trial in Ontario at a university and to get over certain hurdles, and then, when they want to do it in Alberta at the University of Alberta, they find themselves confronted with the same hurdles.
There have been calls to have a national approach to clinical trials, so you come in once, you do your ethics, and you establish protocols. Then, centrally, you're looking for connections to patients to run the trial through. I think it's that kind of innovative approach, perhaps run through CIHR, to look at how we can do the work of research, and patient-oriented research at times, to run it most efficiently.